How HOCM Causes Heart Failure
Hypertrophic obstructive cardiomyopathy causes heart failure through multiple interconnected mechanisms: dynamic left ventricular outflow tract obstruction creating high intracavity pressures, diastolic dysfunction from impaired relaxation and increased chamber stiffness, mitral regurgitation from systolic anterior motion, and myocardial ischemia from supply-demand mismatch. 1, 2
Primary Pathophysiologic Mechanisms
1. Dynamic LVOT Obstruction (Most Common)
The obstruction occurs when:
- Septal hypertrophy narrows the LVOT, creating abnormal blood flow vectors
- Systolic anterior motion (SAM) of the mitral valve results from drag forces pushing elongated mitral leaflets into the outflow tract during systole 3, 1
- This creates a mechanical impedance to LV outflow, leading to markedly elevated intracavity pressures (often >200 mmHg)
Clinical Impact: The high LV systolic pressure from obstruction triggers a cascade of problems:
- Prolonged ventricular relaxation
- Elevated LV diastolic pressures
- Decreased forward cardiac output
- Worsening mitral regurgitation 3
Approximately 75% of HCM patients have obstruction (either at rest or with provocation), and obstruction ≥30 mmHg independently predicts 2-fold increased mortality and 4.4-fold increased risk of progression to severe heart failure 4, 1.
2. Diastolic Dysfunction
This is a major pathophysiologic abnormality arising from multiple factors 3, 5:
Impaired Relaxation:
- High systolic contraction load from outflow obstruction
- Nonuniform ventricular contraction and relaxation
- Delayed inactivation from abnormal intracellular calcium reuptake
- Can occur even in early disease (gene carriers with normal wall thickness)
Increased Chamber Stiffness:
- Severe myocardial hypertrophy
- Diffuse myocardial fibrosis
- Reduced ventricular cavity size compromising stroke volume
Critical Point: Diastolic dysfunction contributes to decreased exercise capacity and adverse prognosis independent of LVOTO 2. Patients become highly dependent on atrial contraction for ventricular filling, explaining why atrial fibrillation is so poorly tolerated.
3. Mitral Regurgitation
MR occurs through two mechanisms 2:
Secondary (from SAM):
- Mid-to-late systolic timing
- Posterior or lateral jet direction
- Results from anterior mitral valve distortion and compromised leaflet coaptation
Primary (structural abnormalities):
- Excessive leaflet length
- Anomalous papillary muscle insertion
- Anteriorly displaced papillary muscles
Both contribute significantly to symptom burden and volume overload.
4. Myocardial Ischemia
Supply-demand mismatch occurs from 5, 2:
- Increased oxygen demand: Massive hypertrophy, hyperdynamic systolic function, high intracavity pressures
- Reduced oxygen supply: Microvascular dysfunction with impaired coronary flow reserve, medial hypertrophy of intramural arterioles, reduced arteriolar density
- This occurs even without epicardial coronary disease
Clinical Progression to Heart Failure
The obstructive form is mechanically reversible 6, 7. When LVOT obstruction is relieved by septal myectomy:
- LV pressures normalize
- Wall stress decreases
- Left atrial size reduces
- Mitral regurgitation resolves (usually without valve surgery)
- 90-95% achieve symptom relief with survival rates of 99%, 98%, and 95% at 1,5, and 10 years 6
The nonobstructive form progresses differently:
- Primarily diastolic dysfunction and restrictive physiology
- Some patients develop end-stage disease with systolic dysfunction (EF ≤50%), characterized by LV remodeling, cavity enlargement, wall thinning, and diffuse myocardial scarring 6
- These patients require standard heart failure therapy (ACE inhibitors, ARBs, beta-blockers, MRAs) and consideration for advanced therapies including transplantation 8
Key Clinical Distinctions
Important Caveat: In HCM, EF <50% indicates significantly impaired systolic function (not the typical <40% threshold), identifying patients with poor prognosis and increased sudden cardiac death risk 8.
Mortality Context: HCM-related heart failure mortality is now <0.5%/year with contemporary management—approximately 20-fold lower than conventional non-HCM heart failure—due to effective septal reduction therapies and comprehensive care 9.
The dynamic nature of obstruction means gradients vary with heart rate, blood pressure, volume status, activity, medications, food, and alcohol intake 2, explaining the variable symptom burden patients experience day-to-day.